Share on StockTwits

Oculus Innovative Sciences (NASDAQ:OCLS) was downgraded by analysts at Sidoti from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Friday.

Oculus Innovative Sciences (NASDAQ:OCLS) traded down 7.60% during mid-day trading on Friday, hitting $3.04. The stock had a trading volume of 173,883 shares. Oculus Innovative Sciences has a 1-year low of $2.20 and a 1-year high of $7.21. The stock’s 50-day moving average is $3.23 and its 200-day moving average is $3.57. The company’s market cap is $22.0 million.

Oculus Innovative Sciences (NASDAQ:OCLS) last announced its earnings results on Thursday, June 12th. The company reported $0.99 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.21) by $1.20. The company had revenue of $2.91 million for the quarter, compared to the consensus estimate of $3.42 million. During the same quarter in the prior year, the company posted ($0.23) earnings per share. Analysts expect that Oculus Innovative Sciences will post $-0.29 EPS for the current fiscal year.

Oculus Innovative Sciences, Inc develops, manufactures and markets a family of tissue care products that cure infections, and through a separate mechanism of action, enhance healing while reducing the need for antibiotics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.